CX-072 (pacmilimab), a Probody(®) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

BACKGROUND: Probody(®) therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing ‘off-tumor’ toxicity. We report dose-escalation and single-agent expansion phase dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Thistlethwaite, Fiona, De Vries, Elisabeth G.E., Eskens, Ferry A.L.M., Uboha, Nataliya, Ott, Patrick A., LoRusso, Patricia, Garcia-Corbacho, Javier, Boni, Valentina, Bendell, Johanna, Autio, Karen A., Randhawa, Manreet, Durm, Greg, Gil-Martin, Marta, Stroh, Mark, Hannah, Alison L., Arkenau, Hendrik-Tobias, Spira, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311335/
https://www.ncbi.nlm.nih.gov/pubmed/34301809
http://dx.doi.org/10.1136/jitc-2021-002447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311335/
https://www.ncbi.nlm.nih.gov/pubmed/34301809
http://dx.doi.org/10.1136/jitc-2021-002447

Ejemplares similares